Barack Obama endorses for Alexandria Ocasio-Cortez

Former President Obama announced Monday he's endorsing progressive House candidate Alexandria Ocasio-Cortez (D).

Obama issued his support for the former organizer for Sen. Bernie Sanders' (I-Vt.) presidential campaign in his second wave of endorsements related to the upcoming midterm elections.

Ocasio-Cortez has received widespread attention from lawmakers since her upset victory over longtime Rep. Joseph Crowley (D-N.Y.) in a June primary election.

[SOURCE: THE HILL]

Former President Barack Obama endorses Andrew Gillum for Florida governor

Former President Barack Obama has endorsed Andrew Gillum to be the next governor of Florida. Gillum has made health care a central plank in his platform and Obama made note of it when he threw his support behind the Democratic nominee Monday morning.

“Andrew believes that health care is a right, not a privilege and he will make expanding Medicaid a priority on day one as governor,” said Obama, whose signature achievement as president was the Affordable Care Act.

“Andrew will expand access to affordable health care, protect Floridians with pre-existing conditions, invest in education, protect the environment and build an economy that works for all,” continued Obama, in a prepared statement.

The endorsement puts the national Democrats' three biggest hitters in the Tallahassee mayor's corner. Vermont Sen. Bernie Sanders campaigned with Gillum during the primary. And former Secretary of State Hillary Clinton will hit the campaign trail with the mayor later this month as he tries to be the first Democrat in 20 years to win a Florida governor's race.

[SOURCE: Tallahahassee.com]

National Institutes of Health launches initiative to accelerate therapies to cure sickle cell disease

The National Institutes of Health (NIH) today announced the launch of a new initiative to help speed the development of a cure for sickle cell disease, a group of inherited blood disorders affecting at least 100,000 people in the United States and 20 million worldwide. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.

“Our scientific investments have brought us to a point where we have many tools available to correct or compensate for the defective gene that causes sickle cell disease. We are now ready to use these tools to speed up our quest for a cure,” said Gary H. Gibbons, M.D., director of NIH’s National Heart, Lung, and Blood Institute (NHLBI), which is leading the effort.

Sickle cell disease results from a single genetic mutation that causes a person’s red blood cells to form an abnormal, sickle shape. These sickled cells can clog the blood vessels and deprive cells of oxygen. In turn, this lack of oxygen wreaks havoc on the body, damaging organs, causing severe pain, and potentially leading to premature death.

Decades of basic research on sickle cell disease have laid the groundwork for novel genetic approaches to cures, such as the genetic editing of bone marrow cells, which have shown great promise in animal models and in some small-scale human studies. In addition, the NHLBI Production Assistance for Cellular Therapies (PACT) program has been working with researchers to manufacture cellular therapeutic products, including genetically modified cells, that can be used safely in clinical trials with patients.

NIH spends approximately $100 million on sickle cell disease research each year. Through this initiative, NHLBI seeks to support the development of cell and genetic therapies resources, clinical trials, comparator analyses of different management strategies, data repositories and resources, and patient and advocate engagement activities related to curative therapies for this condition. Already in 2018, NHLBI committed an additional $7 million to jumpstart the initiative’s research and engagement infrastructure.

NHLBI has named hematologist Edward J. Benz Jr., M.D., President and CEO Emeritus of Dana-Farber Cancer Institute, as the Initiative’s executive director, and the Emmes Corporation, a contract research organization with specialized expertise in clinical trials, gene, and cell therapy development in preclinical studies, as its coordinating center.

The initiative and other research partners will establish a national data warehouse of genetic therapies for sickle cell disease and conduct comparative analyses of therapeutic approaches to assess both clinical and cost-effectiveness. They will also establish national networks to make it easier for patients and providers to learn and engage with the research, clinical trials, and other activities happening across the country.

“The engagement of patients will be a cornerstone of this effort,” said Benz. “Patients will work alongside researchers in developing and recruiting for clinical trials.”

Currently, the only cure for sickle cell disease is a bone marrow transplant, a procedure in which a sick patient receives bone marrow from a healthy, genetically-compatible sibling donor. However, transplants are too risky for many adults, and only about 18 percent of children with the sickle cell disease have a healthy, matched sibling donor.

The Cure Sickle Cell Initiative seeks to develop cures for a far broader group of individuals with the disease, and it is initially focusing on gene therapies that modify the patient’s own hematopoietic stem cells (HSCs), which make red and other blood cells. These modified HSCs can then be given back to the patient via a bone marrow transplant, making a cure available to more patients who lack a matched donor.

“This initiative is giving patients, families, and communities a reason for hope. I’m particularly pleased that we are able to make this announcement during Sickle Cell Awareness month when we are shining a spotlight on the toll of this devastating disease,” said ADM Brett Giroir, M.D. Assistant Secretary for Health at the U.S. Department of Health and Human Services (HHS).

This patient-focused Initiative builds on the legacy of NHLBI-supported research that has contributed to improving clinical care for patients who have sickle cell disease. It also complements the Institute’s broader sickle cell disease research investment, which includes basic, clinical, translational, and implementation science research.

Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at http://www.nhlbi.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health

Sen. Cory Booker statement on FBI investigating Kavanaugh allegations

US Senator Cory Booker (D-NJ) has released the following statement on the FBI investigating the Kavanaugh allegations:

I was encouraged by the good faith discussion with my judiciary colleagues earlier this afternoon, and Senator Jeff Flake in particular. It's my hope that the FBI will conduct a full, fair, and thorough investigation into the allegations against Judge Kavanaugh.

At a minimum, the FBI investigation should include investigating Dr. Ford’s credible allegations in the following ways:

1. Interviewing each witness Ford identified as being present on the night of the assault – Dr. Ford, Judge Kavanaugh, Mark Judge, PJ Smyth, and Leland Keyser.

2. Investigating where and when this assault could’ve taken place and any other potential witnesses.

3. Interviewing Dr. Ford’s polygrapher and the witnesses she spoke to about the assault.

4. Investigating Kavanaugh’s claims regarding these allegations, including following up on the entries in his calendar and interviewing witnesses who have contradicted his statements about his drinking habits around the time of the assault.

This FBI investigation should also include investigating the other allegations that Ms. Ramirez and Ms. Swetnick have made.

Maxine Waters responds to accusations her office leaked GOP senators' information

Rep. Maxine Waters (D-Calif.) has released a statement denied allegations claiming that a member of her staff was responsible for the release of personal information regarding U.S. senators. Read her statement below:

Rep. Waters Statement on False Allegations Regarding the Leak of the Personal Information of U.S. Senators

“Lies, lies, and more despicable lies. I am utterly disgusted by the spread of the completely false, absurd, and dangerous lies and conspiracy theories that are being peddled by ultra-right wing pundits, outlets, and websites who are promoting a fraudulent claim that a member of my staff was responsible for the release of the personal information of Members of the United States Senate on Wikipedia. This unfounded allegation is completely false and an absolute lie.

“The United States Capitol Police and our internal IT specialist have determined that the IP address in question does not belong to my office or anyone on my staff. The member of my staff – whose identity, personal information, and safety have been compromised as a result of these fraudulent and false allegations – was in no way responsible for the leak of this information. My office has alerted the appropriate authorities and law enforcement entities of these fraudulent claims. We will ensure that the perpetrators will be revealed, and that they will be held legally liable for all of their actions that are destructive and dangerous to any and all members of my staff.”